Category Archives: Victoza

Once-Weekly Tanzeum for Type 2s Now Available

Tanzeum (albiglutide), a once-weekly injectable drug for type 2s from GSK (GlaxoSmithKline), USA is now available at pharmacies throughout the United States. The FDA approved U.S. sales on April 15. The drug is a glucagon-like peptide-1 receptor agonist (GLP-1) that can be used in conjunction with other type 2 drugs. GLP-1s work by inducing the … Continue reading Once-Weekly Tanzeum for Type 2s Now Available

Weekly Dulaglutide Performs Well in Comparison to Daily Liraglutide

A comparison of the effects on A1c between users of once-weekly dulaglutide (made by Eli Lilly and Company) and once-daily liraglutide (sold as Victoza from Novo Nordisk) shows that both drugs have very similar effects. Researchers at Ohio State University conducted a nine-country study of 599 type 2 patients, aged 18 years and older, with … Continue reading Weekly Dulaglutide Performs Well in Comparison to Daily Liraglutide

NBA Hall of Famer Dominique Wilkins: Has A Slam Dunk Formula for Diabetes

NBA Hall of Famer Dominique Wilkins, affectionately known as “The Human Highlight Film” has a few coaching tips for people with diabetes. Several years after retiring from the Atlanta Hawks, Dominique was diagnosed with type 2 diabetes. Once he stopped playing professional basketball, he stopped exercising and eating well.  Consequently, he started experiencing some common … Continue reading NBA Hall of Famer Dominique Wilkins: Has A Slam Dunk Formula for Diabetes

FDA Backtracks Over GLP-1s’ Effects on Pancreas

The U.S. Food and Drug Administration reports that its review of various animal and human studies does not show a link between GLP-1 drugs used to treat type 2 diabetes and pancreatic maladies, including acute pancreatitis and pancreatic cancer. GLP-1 drugs, which work by stimulating the body to produce insulin, include Bristol-Myers Squibb’s Byetta and … Continue reading FDA Backtracks Over GLP-1s’ Effects on Pancreas

Weekly Type 2 Drug to Be Delivered Via Needle Patch

A recent agreement between Zosano Pharma, Inc. and Novo Nordisk could lead to the introduction of a once-weekly drug for type 2s that is administered via a micro-needle patch system. The drug, now under development by Novo Nordisk, is semaglutide, a GLP-1 (glucagon-like peptide) receptor agonist that the company is hoping to introduce as a … Continue reading Weekly Type 2 Drug to Be Delivered Via Needle Patch

First-World Type 2 Drug Market to Reach $47 Billion by 2022

A Massachusetts-based research firm concludes that the first-world market for type 2 drugs and treatments will increase from $27 billion in sales in 2012 to $47 billion in 2022. The firm, Decision Resources, says increased sales in the United States, Japan, France, Germany, Italy, Spain, and the United Kingdom, will come from both an increase … Continue reading First-World Type 2 Drug Market to Reach $47 Billion by 2022

Lilly Says Its New Injectible Outperforms Three Popular Diabetes Drugs

Good news for Eli Lilly & Co., as well as for type 2s who appreciate the addition of new drugs to treat their condition: Lilly says its once-weekly injectible drug, dulaglutide, has outperformed three other widely taken diabetes drugs in three just-concluded Phase III studies. According to Lilly, dulaglutide, a GLP-1 analog, worked better to … Continue reading Lilly Says Its New Injectible Outperforms Three Popular Diabetes Drugs

Diabetes Health Type 2: Paula Deen: Cooking Up a New Life With Diabetes

Paula Deen, a celebrity Southern chef known for her unrestrained love of butter and sugar, is no stranger to the media. She received a flurry of bad press recently when she revealed that she had been diagnosed with type 2 diabetes three years earlier. Shortly thereafter, she became a spokesperson for Novo Nordisk’s Victoza. Following … Continue reading Diabetes Health Type 2: Paula Deen: Cooking Up a New Life With Diabetes

Am I Doing the Right Thing?

Readers occasionally ask us for advice about drugs they are taking. When they do, we refer their questions to a medical professional. In the question below, a Florida reader expresses concerns about the interaction of her diabetes drug with the medicines she takes for asthma. Dear Diabetes Health: I am asthmatic and was diagnosed with … Continue reading Am I Doing the Right Thing?

FDA Gives Long-Awaited Nod to Amylin’s Bydureon

After several years of delays and setbacks, Amylin Pharmaceuticals has received FDA approval to begin US marketing of BydureonTM. The first once-a-week type 2 therapy to be offered in the US market, Bydureon is expected to be available by February. Amylin says that its wholesale price will be about $4,200 a year. The drug is … Continue reading FDA Gives Long-Awaited Nod to Amylin’s Bydureon